N-(3-methylbutyl)cyclopropanecarboxamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(3-methylbutyl)cyclopropanecarboxamide
• 化学式: C₉H₁₇NO
• mdl: MFCD03396365
• 分子量: 155.24
• InChiKey: MVZPLZAYSWFQAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1<br/>[FR] NOUVEAUX COMPOSÉS POUR L'INHIBITION DE LA JANUS KINASE 1
  申请人：MANKIND PHARMA LTD

  公开号：WO2020240586A1

  公开（公告）日：2020-12-03

  An object of the invention is to provide compounds as selective JAK1 inhibitor, a process for preparation of the inhibitors, a composition containing the compounds and utility of the compounds.

  本发明的目的是提供作为选择性JAK1抑制剂的化合物，制备抑制剂的方法，含有这些化合物的组合物以及这些化合物的用途。
• Substituted-1-Phthalazinamines As Vr- 1 Antagonists
  申请人：Chakravarty Pasun K.

  公开号：US20090048227A1

  公开（公告）日：2009-02-19

  Substituted piperidine compounds represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.

  以式I表示的取代哌啶化合物，或其药学上可接受的盐。制药组合物包括即时化合物的有效量，可以单独使用，或与一个或多个其他治疗活性化合物结合，并与药学上可接受的载体一起使用。治疗与钠通道活性相关或由其引起的病症的方法，包括例如急性疼痛、慢性疼痛、脏器疼痛、炎症性疼痛、神经病性疼痛、尿失禁、瘙痒、过敏性皮炎、癫痫、肠易激综合症、抑郁症、焦虑症、多发性硬化症和双相障碍，包括单独使用即时化合物的有效量或与一个或多个其他治疗活性化合物结合使用。
• Pyrrolo[2,3d]pyrimidine compositions and their use
  申请人：Castelhano Arlindo L.

  公开号：US20090082369A1

  公开（公告）日：2009-03-26

  This invention pertains to compounds having the structure: wherein R 1 and R 2 together form a substituted or unsubstituted heterocyclic ring; R 3 is a substituted or unsubstituted aryl moiety; R 4 is a hydrogen atom, an unsubstituted alkyl, or a substituted or unsubstituted aryl moiety; and R 5 and R 6 are each independently a halogen atom, a hydrogen atom or a substituted or unsubstituted alkyl, aryl, or alkylaryl moiety, or a pharmaceutically acceptable salt thereof, and the use of these compounds to treat a disease associated with increased levels of adenosine in a subject.

  本发明涉及具有以下结构的化合物：其中R1和R2共同形成取代或未取代的杂环；R3是取代或未取代的芳基基团；R4是氢原子，未取代的烷基或取代或未取代的芳基基团；R5和R6分别独立地是卤素原子，氢原子或取代或未取代的烷基、芳基或烷基芳基基团，或其药学上可接受的盐，并使用这些化合物治疗与受试者中腺苷水平增加相关的疾病。
• TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Babu Srinivasan

  公开号：US20110201593A1

  公开（公告）日：2011-08-18

  The invention provides novel compounds of formula I having the general formula: wherein R 1 , R 2 , R 3 , X and Y are as described herein. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment of immunological or hyperproliferative disorders.

  本发明提供了具有以下一般式的新化合物I： 其中R1、R2、R3、X和Y如本文所述。因此，这些化合物可以在药学上可接受的组合物中提供，并用于治疗免疫或过度增生性疾病。
• PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
  申请人：Gibbons Paul

  公开号：US20120190665A1

  公开（公告）日：2012-07-26

  A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 and R 3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.

  公式I的化合物、对映异构体、顺反异构体、互变异构体或其药学上可接受的盐，其中R1、R2和R3的定义如本文所述，可用作一种或多种Janus激酶的抑制剂。本文还揭示了一种包括公式I的化合物和药学上可接受的载体、辅料或载体的药物组合物，以及治疗或减轻患者对Janus激酶活性抑制响应的疾病或状况的方法。